Heterocyclic esters and amides

ABSTRACT

This invention relates to neurotrophic low molecular weight, small molecule heterocyclic esters and amides having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

This is a divisional application of U.S. patent application Ser. No.09/027,622, filed Feb. 23, 1998, which is a divisional application ofU.S. patent application Ser. No. 08/719,947, filed Sep. 25, 1996 nowU.S. Pat. No. 5,801,187 granted Sep. 1, 1998.

BACKGROUND OF THE INVENTION

1. Field of Invention

This invention relates to neurotrophic low molecular weight, smallmolecule heterocyclic esters and amides having an affinity for FKBP-typeimmunophilins, and their use as inhibitors of the enzyme activityassociated with immunophilin proteins, particularly peptidyl-prolylisomerase, or rotamase, enzyme activity.

2. Description of Related Art

The term immunophilin refers to a number of proteins that serve asreceptors for the principal immunosuppressant drugs, cyclosporin A(CsA), FK506 and rapamycin. Known classes of immunophilins arecyclophilins and FK506 binding proteins, or FKBPs. Cyclosporin A bindsto cyclophilin A while FK506 and rapamycin bind to FKBP12. Theseimmunophilin-drug complexes interface with various intracellular signaltransduction systems, especially the immune and nervous systems.

Immunophilins are known to have peptidyl-prolyl isomerase (PPIase), orrotamase, enzyme activity. It has been determined that rotamase enzymeactivity plays a role in the catalyzation of the interconversion of thecis and trans isomers of peptide and protein substrates for theimmunophilin proteins.

Immunophilins were originally discovered and studied in the immunetissue. It was initially postulated by those skilled in the art thatinhibition of the immunophilins' rotamase activity leads to inhibitionof T-cell proliferation, thereby causing the immunosuppressive activityexhibited by immunosuppressant drugs, such as cyclosporin A, FK506 andrapamycin. Further study has shown that the inhibition of rotamaseactivity, in and of itself, does not result in immunosuppressiveactivity. Schreiber et al., Science, 1990, vol. 250, pp. 556-559.Instead, immunosuppression appears to stem from the formulation of acomplex of immunosuppressant drugs and immunophilins. It has been shownthat the immunophilin-drug complexes interact with ternary proteintargets as their mode of action. Schreiber et al., Cell, 1991, vol. 66,pp. 807-815. In the case of FKBP-FK506 and cyclophilin-CsA, theimmunophilin-drug complexes bind to the enzyme calcineurin and inhibitthe T-cell receptor signalling which leads to T-cell proliferation.Similarly, the immunophilin-drug complex of FKBP-rapamycin interactswith the RAFT1/FRAP protein and inhibits the IL-2 receptor signalling.

Immunophilins have been found to be present at high concentrations inthe central nervous system. Immunophilins are enriched 10-50 times morein the central nervous system than in the immune system. Within neuraltissues, immunophilins appear to influence nitric oxide synthesis,neurotransmitter release and neuronal process extension.

It has been found that picomolar concentrations of an immunosuppressantsuch as FK506 and rapamycin stimulate neurite outgrowth in PC12 cellsand sensory neurons, namely dorsal root ganglion cells (DRGs). Lyons etal., Proc. of Natl. Acad. Sci., 1994, vol. 91, pp. 3191-3195. In wholeanimal experiments, FK506 has been shown to stimulate nerve regenerationfollowing facial nerve injury.

Surprisingly, it has been found that certain compounds with a highaffinity for FKBPs are potent rotamase inhibitors and exhibit excellentneurotrophic effects. Furthermore, these rotamase inhibitors are devoidof immunosuppressive activity. These findings suggest the use ofrotamase inhibitors in treating various peripheral neuropathies andenhancing neuronal regrowth in the central nervous system (CNS). Studieshave demonstrated that neurodegenerative disorders such as Alzheimer'sdisease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)may occur due to the loss, or decreased availability, of a neurotrophicsubstance specific for a particular population of neurons affected inthe disorder.

Several neurotrophic factors affecting specific neuronal populations inthe central nervous system have been identified. For example, it hasbeen hypothesized that Alzheimer's disease results from a decrease orloss of nerve growth factor (NGF). It has thus been proposed to treatSDAT patients with exogenous nerve growth factor or other neurotrophicproteins, such as brain derived growth factor, glial derived growthfactor, ciliary neurotrophic factor and neurotropin-3, to increase thesurvival of degenerating neuronal populations.

Clinical application of these proteins in various neurological diseasestates is hampered by difficulties in the delivery and bioavailabilityof large proteins to nervous system targets. By contrast,immunosuppressant drugs with neurotrophic activity are relatively smalland display excellent bioavailability and specificity. However, whenadministered chronically, immunosuppressant drugs exhibit a number ofpotentially serious side effects including nephrotoxicity, such asimpairment of glomerular filtration and irreversible interstitialfibrosis (Kopp et al., J. Am. Soc. Nephrol., 1991, 1:162); neurologicaldeficits, such as involuntary tremors, or non-specific cerebral angina,such as non-localized headaches (De Groen et al., N. Engl. J. Med.,1987, 317:861); and vascular hypertension with complications resultingtherefrom (Kahan et al., N. Engl. J. Med., 1989, 321:1725).

In order to prevent the side effects associated with use of theimmunosuppressant compounds, the present invention providesnon-immunosuppressive compounds containing small molecule FKBP rotamaseinhibitors for enhancing neurite outgrowth, and promoting neuronalgrowth and regeneration in various neuropathological situations whereneuronal repair can be facilitated, including: peripheral nerve damagecaused by physical injury or disease state such as diabetes; physicaldamage to the central nervous system (spinal cord and brain); braindamage associated with stroke; and neurological disorders relating toneurodegeneration, such as Parkinson's disease, SDAT (Alzheimer'sdisease), and amyotrophic lateral sclerosis.

SUMMARY OF THE INVENTION

The present invention relates to neurotrophic low molecular weight,small molecule compounds having an affinity for FKBP-type immunophilins.Once bound to these proteins, the neurotrophic compounds are potentinhibitors of the enzyme activity associated with immunophilin proteins,particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity. Akey feature of the compounds of the present invention is that they donot exert any significant immunosuppressive activity in addition totheir neurotrophic activity.

Specifically, the present invention relates to a compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

A and B, together with the nitrogen and carbon atoms to which they arerespectively attached, form a 5-7 membered saturated or unsaturatedheterocyclic ring containing, in addition to the nitrogen atom, at leastone additional O, S, SO, SO₂, NH or NR₁ heteroatom in any chemicallystable oxidation state;

X is O or S;

Z is O, NH or NR_(1;)

W and Y are independently O, S, CH₂ or H_(2;)

R₁ is C₁-C₆ straight or branched chain alkyl or alkenyl, which issubstituted in one or more position(s) with (Ar₁)_(n), (Ar₁)_(n)connected by a C₁-C₆ straight or branched chain alkyl or alkenyl, C₃-C₈cycloalkyl, C₃-C₈ cycloalkyl connected by a C₁-C₆ straight or branchedchain alkyl or alkenyl, Ar₂, or a combination thereof;

n is 1 or 2;

R₂ is either C₁-C₉ straight or branched chain alkyl or alkenyl, C₃-C₈cycloalkyl, C₅-C₇ cycloalkenyl, or Ar₁, wherein said alkyl, alkenyl,cycloalkyl or cycloalkenyl is either unsubstituted or substituted in oneor more position(s) with C₁-C₄ straight or branched chain alkyl oralkenyl, hydroxyl, or a combination thereof; and

Ar₁ and Ar₂ are independently a mono-, bi- or tricyclic, carbo- orheterocyclic ring, wherein the ring is either unsubstituted orsubstituted in one to three position(s) with halo, hydroxyl, nitro,trifluoromethyl, C₁-C₆ straight or branched chain alkyl or alkenyl,C₁-C₄ alkoxy, C₁-C₄ alkenyloxy, phenoxy, benzyloxy, amino, or acombination thereof; wherein the individual ring sizes are 5-6 members;and wherein the heterocyclic ring contains 1-6 heteroatom(s) selectedfrom the group consisting of O, N, S, and a combination thereof.

A preferred embodiment of this invention is a compound of formula II:

or a pharmaceutically acceptable salt thereof, wherein:

A, B and C are independently CH₂, O, S, SO, SO₂, NH or NR₁;

R₁ is C₁-C₅ straight or branched chain alkyl or alkenyl, which issubstituted in one or more position(s) with (Ar₁)_(n), (Ar₁)_(n)connected by a C₁-C₆ straight or branched chain alkyl or alkenyl, or acombination thereof;

n is 1 or 2;

R₂ is either C₁-C₉ straight or branched chain alkyl or alkenyl, C₃-C₈cycloalkyl, C₅-C₇ cycloalkenyl, or Ar₁; and

Ar₁ is a mono-, bi- or tricyclic, carbo- or heterocyclic ring, whereinthe ring is either unsubstituted or substituted in one to threeposition(s) with halo, hydroxyl, nitro, trifluoromethyl, C₁ -C₆ straightor branched chain alkyl or alkenyl, C₁-C₄ alkoxy, C₁-C₄ alkenyloxy,phenoxy, benzyloxy, amino, or a combination thereof; wherein theindividual ring sizes are 5-6 members; and wherein the heterocyclic ringcontains 1-6 heteroatom(s) selected from the group consisting of O, N,S, and a combination thereof.

Another preferred embodiment is a compound of formula III:

or a pharmaceutically acceptable salt thereof, wherein:

A, B, C and D are independently CH₂, O, S, SO, SO₂, NH or NR R₁;

R₁ is C₁-C₅ straight or branched chain alkyl or alkenyl, which issubstituted in one or more position(s) with (Ar₁)_(n), (Ar₁)_(n)connected by a C₁-C₆ straight or branched chain alkyl or alkenyl, or acombination thereof;

n is 1 or 2;

R₂ is either C₁-C₉ straight or branched chain alkyl or alkenyl, C₃-C₈cycloalkyl, C₅-C₇ cycloalkenyl, or Ar₁; and

Ar₁ is a mono-, bi- or tricyclic, carbo- or heterocyclic ring, whereinthe ring is either unsubstituted or substituted in one to threeposition(s) with halo, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straightor branched chain alkyl or alkenyl, C₁-C₄ alkoxy, C₁-C₄ alkenyloxy,phenoxy, benzyloxy, amino, or a combination thereof; wherein theindividual ring sizes are 5-6 members; and wherein the heterocyclic ringcontains 1-6 heteroatom(s) selected from the group consisting of O, N,S, and a combination thereof.

The present invention also relates to a pharmaceutical compositioncomprising a neurotrophically effective amount of the compound offormula I, II or III, and a pharmaceutically acceptable carrier.

The present invention further relates to a method of effecting aneuronal activity in an animal, comprising:

administering to the animal a neurotrophically effective amount of thecompound of formula I, II or III.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1(A) is a representative photomicrograph of compound 1 (1 pM)promoting neurite outgrowth in sensory neurons.

FIG. 1(B) is a representative photomicrograph of compound 1 (10 pM)promoting neurite outgrowth in sensory neurons.

FIG. 1(C) is a representative photomicrograph of compound 1 (100 pM)promoting neurite outgrowth in sensory neurons.

FIG. 2(A) is a representative photomicrograph of compound 2 (10 pM)promoting neurite outgrowth in sensory neurons.

FIG. 2(B) is a representative photomicrograph of compound 2 (100 pM)promoting neurite outgrowth in sensory neurons.

FIG. 2(C) is a representative photomicrograph of compound 2 (10 nM)promoting neurite outgrowth in sensory neurons.

DETAILED DESCRIPTION OF THE INVENTION Definitions

“Alkyl” means a branched or unbranched saturated hydrocarbon chaincontaining 1 to 6 carbon atoms, such as methyl, ethyl, propyl,iso-propyl, butyl, iso-butyl, tert-butyl, n-pentyl, n-hexyl, and thelike, unless otherwise indicated.

“Alkoxy” means the group —OR wherein R is alkyl as herein defined.Preferably, R is a branched or unbranched saturated hydrocarbon chaincontaining 1 to 3 carbon atoms.

“Halo” means fluoro, chloro, bromo, or iodo, unless otherwise indicated.

“Phenyl” includes all possible isomeric phenyl radicals, optionallymonosubstituted or multi-substituted with substituents selected from thegroup consisting of alkyl, alkoxy, hydroxy, halo, and haloalkyl.

The term “pharmaceutically acceptable salt” refers to salts of thesubject compounds which posses the desired pharmacological activity andwhich are neither biologically nor otherwise undesirable. The salts canbe formed with inorganic acids such as acetate, adipate, alginate,aspartate, benzoate, benzenesulfonate, bisulfate butyrate, citrate,camphorate, camphorsulfonate, cyclopentanepropionate, digluconate,dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate,glycerophosphate, hemisulfate heptanoate, hexanoate, hydrochloridehydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate,thiocyanate, tosylate and undecanoate. Base salts include ammoniumsalts, alkali metal salts such as sodium and potassium salts, alkalineearth metal salts such as calcium and magnesium salts, salt with organicbases such as dicyclohexylamine salts, N-methyl-D-glucamine, and saltswith amino acids such as arginine, lysine, and so forth. Also, the basicnitrogen-containing groups can be quarternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl chloride,bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyland diamyl sulfates, long chain halides such as decyl, lauryl, myristyland stearyl chlorides, bromides and iodides, aralkyl halides like benzyland phenethyl bromides and others. Water or oil-soluble or dispersibleproducts are thereby obtained.

The compounds of this invention possess asymmetric centers and thus canbe produced as mixtures of stereoisomers or as individual stereoisomers.The individual stereoisomers may be obtained by using an opticallyactive starting material, by resolving a racemic or non-racemic mixtureof an intermediate at some appropriate stage of the synthesis, or byresolution of the compound of formula (I). It is understood that theindividual stereoisomers as well as mixtures (racemic and non-racemic)of stereoisomers are encompassed by the scope of the present invention.The compounds of this invention possess at least one asymmetric centersand thus can be produced as mixtures of stereoisomers or as individualR- and S-stereoisomers. The individual enantiomers may be obtained byresolving a racemic or non-racemic mixture of an intermediate at someappropriate stage of the synthesis. It is understood that the individualR- and S- stereoisomers as well as mixtures of stereoisomers areencompassed by this invention. The S-stereoisomer is most preferred dueto its greater activity.

“Isomers” are different compounds that have the same molecular formula.

“Stereoisomers” are isomers that differ only in the way the atoms arearranged in space.

“Enantiomers” are a pair of stereoisomers that are non-superimposablemirror images of each other.

“Diastereoisomers” are stereoisomers which are not mirror images of eachother.

“Racemic mixture” means a mixture containing equal parts of individualenantiomers. “Non-racemic mixture” is a mixture containing unequal partsof individual enantiomers or stereoisomers.

The term “treatment” as used herein covers any treatment of a diseaseand/or condition in an animal, particularly a human, and includes:

(i) preventing a disease and/or condition from occurring in a subjectwhich may be predisposed to the disease and/or condition but has not yetbeen diagnosed as having it;

(ii) inhibiting the disease and/or condition, i.e., arresting itsdevelopment; or

(iii) relieving the disease and/or condition, i.e., causing regressionof the disease and/or condition.

The system used in naming the compounds of the present invention isshown below, using a compound of formula II as an example.

A compound of formula II wherein A is CH₂, B is S, C is CH₂, R₁ is3-phenylpropyl and R₂ is 3,3-dimethylpentyl, is named3-phenyl-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine)carboxylate.

Compounds of the Invention

The neurotrophic low molecular weight, small molecule FKBP inhibitorcompounds of this invention have an affinity for FKBP-typeimmunophilins, such as FKBP12. When the neurotrophic compounds of thisinvention are bound to an FKBP-type immunophilin, they have been foundto inhibit the prolyl-peptidyl cis-trans isomerase activity, orrotamase, activity of the binding protein and unexpectedly stimulateneurite growth.

Formula I

In particular, this invention relates to a compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

A and B, together with the nitrogen and carbon atoms to which they arerespectively attached, form a 5-7 membered saturated or unsaturatedheterocyclic ring containing, in addition to the nitrogen atom, at leastone additional O, S, SO, SO₂, NH or NR₁ heteroatom in any chemicallystable oxidation state;

X is O or S;

Z is O, NH or NR₁;

W and Y are independently O, S, CH₂ or H₂;

R₁ is C₁-C₆ straight or branched chain alkyl or alkenyl, which issubstituted in one or more position(s) with (Ar₁)_(n), (Ar₁)_(n)connected by a C₁-C₆ straight or branched chain alkyl or alkenyl, C₃-C₈cycloalkyl, C₃-C₈ cycloalkyl connected by a C₁-C₆ straight or branchedchain alkyl or alkenyl, Ar₂, or a combination thereof;

n is 1 or 2;

R₂ is either C₁-C₉ straight or branched chain alkyl or alkenyl, C₃-C₈cycloalkyl, C₅-C₇ cycloalkenyl, or Ar₁, wherein said alkyl, alkenyl,cycloalkyl or cycloalkenyl is either unsubstituted or substituted in oneor more position(s) with C₁-C₄ straight or branched chain alkyl oralkenyl, hydroxyl, or a combination thereof; and

Ar₁ and Ar₂ are independently a mono-, bi- or tricyclic, carbo- orheterocyclic ring, wherein the ring is either unsubstituted orsubstituted in one to three position(s) with halo, hydroxyl, nitro,trifluoromethyl, C₁-C₆ straight or branched chain alkyl or alkenyl,C₁-C₄ alkoxy, C₁-C₄ alkenyloxy, phenoxy, benzyloxy, amino, or acombination thereof; wherein the individual ring sizes are 5-6 members;and wherein the heterocyclic ring contains 1-6 heteroatom(s) selectedfrom the group consisting of O, N, S, and a combination thereof.

The mono- and bicyclic, carbo- and heterocyclic rings include withoutlimitation naphthyl, indolyl, furyl, thiazolyl, thienyl, pyridyl,quinolinyl, isoquinolinyl, fluorenyl and phenyl.

Formula II

A preferred embodiment of this invention is a compound of formula II:

or a pharmaceutically acceptable salt thereof, wherein:

A, B and C are independently CH₂, O, S, SO, SO₂, NH or NR₁;

R₁ is C₁-C₅ straight or branched chain alkyl or alkenyl, which issubstituted in one or more positions) with (Ar₁)_(n), (Ar₁)_(n)connected by a C₁-C₆ straight or branched chain alkyl or alkenyl, or acombination thereof;

n is 1 or 2;

R₂ is either C₁-C₉ straight or branched chain alkyl or alkenyl, C₃-C₈cycloalkyl, C₅-C₇ cycloalkenyl, or Ar₁; and

Ar₁ is a mono-, bi- or tricyclic, carbo- or heterocyclic ring, whereinthe ring is either unsubstituted or substituted in one to threeposition(s) with halo, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straightor branched chain alkyl or alkenyl, C₁-C₄ alkoxy, C₁-C₄ alkenyloxy,phenoxy, benzyloxy, amino, or a combination thereof; wherein theindividual ring sizes are 5-6 members; and wherein the heterocyclic ringcontains 1-6 heteroatom(s) selected from the group consisting of O, N,S, and a combination thereof.

In a particularly preferred embodiment of formula II compounds:

A is CH₂;

B is CH₂ or S;

C is CH₂ or NH;

R₁ is selected from the group consisting of 3-phenylpropyl and3-(3-pyridyl)propyl; and

R₂ is selected from the group consisting of 3,3-dimethylpentyl,cyclohexyl, and tert-butyl.

Specific exemplifications of this embodiment are presented in TABLE I.

TABLE I No. A B C R₁ R₂ 1 CH₂ S CH₂ 3-phenylpropyl 3,3-dimethylpentyl 2CH₂ S CH₂ 3-(3-pyridyl)propyl 3,3-dimethylpentyl 3 CH₂ S CH₂3-phenylpropyl cyclohexyl 4 CH₂ S CH₂ 3-phenylpropyl tert-butyl 5 CH₂CH₂ NH 3-phenylpropyl 3,3-dimethylpentyl 6 CH₂ CH₂ NH 3-phenylpropylcyclohexyl 7 CH₂ CH₂ NH 3-phenylpropyl tert-butyl

Formula III

Another preferred embodiment of this invention is a compound of formulaIII:

or a pharmaceutically acceptable salt thereof, wherein:

A, B, C and D are independently CH₂, O, S, SO, SO₂, NH or NR₁;

R₁ is C₁-C₅ straight or branched chain alkyl or alkenyl, which issubstituted in one or more position(s) with (Ar₁)_(n), (Ar₁)_(n)connected by a C₁-C₆ straight or branched chain alkyl or alkenyl, or acombination thereof;

n is 1 or 2;

R₂ is either C₁-C₉ straight or branched chain alkyl or alkenyl, C₃-C₈cycloalkyl, C₅-C₇ cycloalkenyl, or Ar₁; and

Ar₁ is a mono-, bi- or tricyclic, carbo- or heterocyclic ring, whereinthe ring is either unsubstituted or substituted in one to threeposition(s) with halo, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straightor branched chain alkyl or alkenyl, C₁-C₄ alkoxy, C₁-C₄ alkenyloxy,phenoxy, benzyloxy, amino, or a combination thereof; wherein theindividual ring sizes are 5-6 members; and wherein the heterocyclic ringcontains 1-6 heteroatom(s) selected from the group consisting of O, N,S, and a combination thereof.

In a particularly preferred embodiment of formula III compounds:

A is CH₂;

B is CH₂;

C is S, O or NH;

D is CH₂;

R₁ is selected from the group consisting of 3-phenylpropyl and(3,4,5-trimethoxy)phenylpropyl; and

R₂ is selected from the group consisting of 3,3-dimethylpentyl,cyclohexyl, 3-3-dimethylpropyl, phenyl, and 3,4,5-trimethoxyphenyl.

Specific exemplifications of this embodiment are presented in TABLE II.

TABLE II No. A B C D R₁ R₂  8 CH₂ CH₂ S CH₂ 3-phenylpropyl3,3-dimethylpentyl  9 CH₂ CH₂ O CH₂ 3-phenylpropyl 3,3-dimethylpentyl 10CH₂ CH₂ S CH₂ 3-phenylpropyl cyclohexyl 11 CH₂ CH₂ O CH₂ 3-phenylpropylcyclohexyl 12 CH₂ CH₂ S CH₂ 3-phenylpropyl phenyl 13 CH₂ CH₂ O CH₂3-phenylpropyl phenyl 14 CH₂ CH₂ NH CH₂ 3-phenylpropyl3,3-dimethylpentyl 15 CH₂ CH₂ NH CH₂ 3-phenylpropyl phenyl

The compounds of the present invention exist as stereoisomeric forms,either enantiomers or diastereoisomers. Included within the scope of theinvention are the enantiomers, the racemic form, and diastereoisomericmixtures. Enantiomers and diastereoisomers can be separated by methodsknown to those skilled in the art.

Methods of Using the Compounds of the Invention

The compounds of the present invention have an affinity for the FK506binding protein, particularly FKBP12, which is present in the brain.When the inventive compounds bind to FKBP in the brain, they exhibitexcellent neurotrophic activity. This activity is useful in thestimulation of damaged neurons, the promotion of neuronal regeneration,the prevention of neurodegeneration, and the treatment of severalneurological disorders known to be associated with neuronal degenerationand peripheral neuropathies.

For the foregoing reasons, the present invention further relates to amethod of effecting a neuronal activity in an animal, comprising:

administering to the animal a neurotrophically effective amount of acompound of formula I, II or III.

In a preferred embodiment, the neuronal activity is selected from thegroup consisting of stimulation of damaged neurons, promotion ofneuronal regeneration, prevention of neurodegeneration and treatment ofneurological disorder.

The neurological disorders that may be treated include but are notlimited to: trigeminal neuralgia; glossopharyngeal neuralgia; Bell'sPalsy; myasthenia gravis; muscular dystrophy; amyotrophic lateralsclerosis; progressive muscular atrophy; progressive bulbar inheritedmuscular atrophy; herniated; ruptured or prolapsed invertabrae disksyndromes; cervical spondylosis; plexus disorders; thoracic outletdestruction syndromes; peripheral neuropathic such as those caused bylead, dapsone, ticks, porphyria, or Gullain-Barré syndrome; Alzheimer'sdisease; and Parkinson's disease.

The compounds of the present invention are particularly useful fortreating a neurological disorder selected from the group consisting of:peripheral neuropathy caused by physical injury or disease state,physical damage to the brain, physical damage to the spinal cord, strokeassociated with brain damage, and neurological disorder relating toneurodegeneration. Examples of neurological disorders relating toneurodegeneration are Alzheimer's Disease, Parkinson's Disease, andamyotrophic lateral sclerosis.

For these purposes the compounds of the present invention may beadministered orally, parenterally, by inhalation spray, topically,rectally, nasally, buccally, vaginally or via an implanted reservoir indosage formulations containing conventional non-toxicpharmaceutically-acceptable carriers, adjuvants and vehicles. The termparenteral as used herein includes subcutaneous, intravenous,intramuscular, intraperitoneally, intrathecally, intraventricularly,intrasternal and intracranial injection or infusion techniques.

To be effective therapeutically as central nervous system targets, thecompounds of the present invention should readily penetrate theblood-brain barrier when peripherally administered. Compounds whichcannot penetrate the blood-brain barrier can be effectively administeredby an intraventricular route.

The compounds of the present invention may be administered in the formof sterile injectable preparations, for example, as sterile injectableaqueous or oleaginous suspensions. These suspensions may be formulatedaccording to techniques known in the art using suitable dispersing orwetting agents and suspending agents. The sterile injectablepreparations may also be sterile injectable solutions or suspensions innon-toxic parenterally-acceptable diluents or solvents, for example, assolutions in 1,3-butanediol. Among the acceptable vehicles and solventsthat may be employed are water, Ringer's solution and isotonic sodiumchloride solution. in addition, sterile, fixed oils are conventionallyemployed as solvents or suspending mediums. For this purpose, any blandfixed oil may be employed including synthetic mono- or di-glycerides.Fatty acids such as oleic acid and its glyceride derivatives, includingolive oil and castor oil, especially in their polyoxyethylated versions,are useful in the preparation of injectables. These oil solutions orsuspensions may also contain long-chain alcohol diluents or dispersants.

The compounds may be administered orally in the form of capsules,tablets, aqueous suspensions or solutions. Tablets may contain carrierssuch as lactose and corn starch, and/or lubricating agents such asmagnesium stearate. Capsules may contain diluents including lactose anddried corn starch. Aqueous suspensions may contain emulsifying andsuspending agents combined with the active ingredient. The oral dosageforms may further contain sweetening and/or flavoring and/or coloringagents.

The compounds of this invention may also be administered rectally in theform of suppositories. These compositions can be prepared by mixing thedrug with a suitable non-irritating excipient which is solid at roomtemperature, but liquid at rectal temperature and, therefore, will meltin the rectum to release the drug. Such materials include cocoa butter,beeswax and polyethylene glycols.

The compounds of this invention may also be administered topically,especially when the conditions addressed for treatment involve areas ororgans readily accessible by topical application, including neurologicaldisorders of the eye, the skin, or the lower intestinal tract. Suitabletopical formulations are readily prepared for each of these areas.

For topical application to the eye, or ophthalmic use, the compounds canbe formulated as micronized suspensions in isotonic, pH adjusted sterilesaline, or, preferably, as solutions in isotonic, pH adjusted sterilesaline, either with or without a preservative such as benzylalkoniumchloride. Alternatively for the ophthalmic uses the compounds may beformulated in an ointment such as petrolatum.

For topical application to the skin, the compounds can be formulated ina suitable ointment containing the compound suspended or dissolved in,for example, a mixture with one or more of the following: mineral oil,liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylenepolyoxypropylene compound, emulsifying wax and water. Alternatively, thecompounds can be formulated in a suitable lotion or cream containing theactive compound suspended or dissolved in, for example, a mixture of oneor more of the following: mineral oil, sorbitan monostearate,polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol,benzyl alcohol and water.

Topical application for the lower intestinal tract an be effected in arectal suppository formulation (see above) or in a suitable enemaformulation.

Dosage levels on the order of about 0.1 mg to about 10,000 mg of theactive ingredient compound are useful in the treatment of the aboveconditions, with preferred levels of about 0.1 mg to about 1,000 mg. Theamount of active ingredient that may be combined with the carriermaterials to produce a single dosage form will vary depending upon thehost treated and the particular mode of administration.

It is understood, however, that a specific dose level for any particularpatient will depend upon a variety of factors including the activity ofthe specific compound employed, the age, body weight, general health,sex, diet, time of administration, rate of excretion, drug combination,and the severity of the particular disease being treated and form ofadministration.

The compounds can be administered with other neurotrophic agents such asneurotrophic growth factor (NGF), glial derived growth factor, brainderived growth factor, ciliary neurotrophic factor, and neurotropin-3.The dosage level of other neurotrophic drugs will depend upon thefactors previously stated and the neurotrophic effectiveness of the drugcombination.

Pharmaceutical Compositions of the Invention

The present invention also relates to a pharmaceutical compositioncomprising:

(i) a neurotrophically effective amount of the compound of formula I, IIor III, and

(ii) a pharmaceutically acceptable carrier.

The above discussion relating to the utility and administration of thecompounds of the present invention also applies to the pharmaceuticalcompositions of the present invention.

EXAMPLES

The following examples are illustrative of the present invention and arenot intended to be limitations thereon. Unless otherwise specified, allpercentages are based on 100% by weight of the final compound.

Example 1 Synthesis of3-phenyl-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine)carboxylate(1)

1-(1,2-dioxo-2-methoxyethyl)2-(4-thiazolidine)-carboxylate. A solutionof L-thioproline (1.51 g; 11.34 mmol) in 40 mL of dry methylene chloridewas cooled to 0° C. and treated with 3.3 mL (2.41 g; 23, 81 mmol) oftriethylamine. After stirring this mixture for 30 minutes, a solution ofmethyl oxalyl chloride (1.81 g; 14.74 mmol) was added dropwise. Theresulting mixture was stirred at 0° C. for 1.5 hours, filtered throughCelite to remove solids, dried and concentrated. The crude material waspurified on a silic gel column, eluting with 10% MeOH in methylenechloride, to obtain 2.0 g of the oxamate as an orange-yellow solid.

3-phenyl-1-propyl(2S)-1-(1,2-dioxo-2-methoxyethyl)2-(4-thiazolidine)carboxylate.1-(1,2-dioxo-2-methoxyethyl)2-(4-thiazolidine)carboxylate (500 mg; 2.25mmol), 3-phenyl-1-propanol (465 mg; 3.42 mmol), dicyclohexylcarbodiimide(750 mg; 3.65 mmol), 4-dimethylaminopyridine (95 mg; 0.75 mmol) andcamphorsulfonic acid (175 mg; 0.75 mmol) in 30 mL of methylene chloridewere stirred together overnight. The mixture was filtered through Celiteto remove solids and chromatographed (25% ethyl acetate/hexane) toobtain 690 mg of material, ¹H NMR (CDCl₃, 300 MHz): δ1.92-2.01 (m, 2H);2.61-2.69 (m, 2H); 3.34 (m, 1H); 4.11-4.25 (m, 2H); 4.73 (m, 1H); 5.34(m, 1H); 7.12 (m, 3H); 7.23 (m, 2H).

3-phenyl-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine)carboxylate(1). A solution of3-phenyl-1-propyl(2S)-1-(1,2-dioxo-2-methoxyethyl)2-(4-thiazolidine)carboxylate(670 mg; 1.98 mmol) in tetrahydrofuran (10 mL) was cooled to −78° C. andtreated with 2.3 mL of a 1.0 M solution of 1,1-dimethylpropylmagnesiumchloride in ether. After stirring the mixture for 3 hours, it was pouredinto saturated ammonium chloride, extracted into ethyl acetate, and theorganic phase was washed with water, dried and concentrated. The crudematerial was purified on a silica gel column, eluting with 25% ethylacetate in hexane, to obtain 380 mg of the compound of Example 1 as ayellow oil, ¹H NMR (CDCl₃, 300 MHz): d 0.86 (t, 3H); 1.21 (s, 3H); 1.26(s, 3H); 1.62-1.91 (m, 3H); 2.01 (m, 2H); 2.71 (m, 2H); 3.26-3.33 (m,2H); 4.19 (m, 2H); 4.58 (m, 1H); 7.19 (m, 3H); 7.30 (m, 2H). Anal. Clcd.for C₂₀H₂₇NO₄S: C, 63.63; H, 7.23; N, 3.71. Found: C, 64.29; H, 7.39; N,3.46.

Example 2 Synthesis of3-(3-pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine)carboxylate (2)

The compound of Example 2 was prepared according to the procedure ofExample 1, using 3-(3-pyridyl)-1-propanol in the final step, to yield3-(3-pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine)carboxylate,¹H NMR (CDCl₃, 300 MHz): δ0.89 (t, 3H, J=7.3); 1.25 (s, 3H); 1.28 (s,3H); 1.77 (q, 2H, J=7.3); 2.03 (tt, 2H, J=6.4, 7.5); 2.72 (t, 2H,J=7.5); 3.20 (dd, 1H, J=4.0, 11.8); 3.23 (dd, 1H, J=7.0, 11.8); 4.23 (t,2H, J=6.4); 4.55 (d, 2H, J=8.9); 5.08 (dd, 1H, J=4.0, 7.0); 7.24 (m,1H); 8.48 (m, 2H). Anal. Calcd. for C₁₉H₂₆N₂O₄S−0.5 H₂O: C, 58.89; H,7.02; N, 7.23. Found: C, 58.83; H, 7.05; N, 7.19.

As discussed above, the compounds of the present invention have anaffinity for the FK506 binding protein, particularly FKBP12. Theinhibition of the prolyl peptidyl cis-trans isomerase activity of FKBPmay be measured as an indicator of this affinity.

Ki Test Procedure

Inhibition of the peptidyl-prolyl isomerase (rotamase) activity of theinventive compounds can be evaluated by known methods described in theliterature (Harding, et al., Nature, 1989, 341:758-760; Holt et al. J.Am. Chem. Soc., 115:9923-9938). These values are obtained as apparentKi's and are presented in Table III. The cis-trans isomerization of analanine-proline bond in a model substrate,N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, is monitoredspectrophotometrically in a chymotrypsin-coupled assay, which releasespara-nitroanilide from the trans form of the substrate. The inhibitionof this reaction caused by the addition of different concentrations ofinhibitor is determined, and the data is analyzed as a change infirst-order rate constant as a function of inhibitor concentration toyield the apparent Ki values.

In a plastic cuvette are added 950 mL of ice cold assay buffer (25 mMHEPES, pH 7.8, 100 mM NaCl), 10 mL of FKBP (2.5 mM in 10 mM Tris-Cl pH7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 mL of chymotrypsin (50 mg/mlin 1 mM HCl) and 10 mL of test compound at various concentrations indimethyl sulfoxide. The reaction is initiated by the addition of 5 mL ofsubstrate (succinyl-Ala-Phe-Pro-Phe-para-nitroanilide, 5 mg/mL in 2.35mM LiCl in trifluoroethanol).

The absorbance at 390 nm versus time is monitored for 90 seconds using aspectrophotometer and the rate constants are determined from theabsorbance versus time data files.

The data for these experiments for representative compounds arepresented in Table III under the column “Ki”.

The neurotrophic effects of the compounds of the present invention canbe demonstrated in cellular biological experiments in vitro, asdescribed below.

Chick Dorsal Root Ganglion Cultures and Neurite Outgrowth

Dorsal root ganglia were dissected from chick embryos of ten daygestation. Whole ganglion explants were cultured on thin layerMatrigel-coated 12 well plates with Liebovitz L15 plus high glucosemedia supplemented with 2 mM glutamine and 10% fetal calf serum, andalso containing 10 μM cytosine β-D arabinofuranoside (Ara C) at 37° C.in an environment containing 5% CO₂. Twenty-four hours later, the DRGswere treated with various immunophilin ligands. Forty-eight hours afterdrug treatment, the ganglia were visualized under phase contrast orHoffman Modulation contrast with a Zeiss Axiovert inverted microscope.Photomicrographs of the explants were made, and neurite outgrowth wasquantitated. Neurites longer than the DRG diameter were counted aspositive, with total number of neurites quantitated per eachexperimental condition. Three to four DRGs are cultured per well, andeach treatment was performed in duplicate.

The data for these experiments for representative compounds arepresented in the “ED50” column of Table III. Representativephotomicrographs of compounds 1 (1 pM, 10 pM, 100 pM) and 2 (10 pM, 100pM, 10 nM) promoting neurite outgrowth in sensory neurons are shown inFIGS. 1(A-C) and 2(A-C), respectively.

TABLE III In Vitro Test Results Compound Ki, nM ED50, nM 1 215 0.031 2638 2.0

All publications and patents identified above are hereby incorporated byreference.

The invention being thus described, it will be obvious that the same maybe varied in many ways. Such variations are not to be regarded as adeparture from the spirit and scope of the invention and all suchmodifications are intended to be included within the scope of thefollowing claims.

What is claimed is:
 1. The compound1-(1,2-dioxo-2-methoxyethyl)2-(4-thiazolidine) carboxylic acid.